ATE199392T1 - Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung - Google Patents

Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung

Info

Publication number
ATE199392T1
ATE199392T1 AT94902030T AT94902030T ATE199392T1 AT E199392 T1 ATE199392 T1 AT E199392T1 AT 94902030 T AT94902030 T AT 94902030T AT 94902030 T AT94902030 T AT 94902030T AT E199392 T1 ATE199392 T1 AT E199392T1
Authority
AT
Austria
Prior art keywords
pct
date
multivalent
domains
sec
Prior art date
Application number
AT94902030T
Other languages
English (en)
Inventor
Kaspar-Philipp Holliger
Andrew David Griffiths
Hendricus Renerus J Hoogenboom
Magnus Malmqvist
James David Marks
Brian Timothy Mcguinness
Anthony Richard Pope
Terence Derek Prospero
Gregory Paul Winter
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27442661&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE199392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929225453A external-priority patent/GB9225453D0/en
Priority claimed from GB939300816A external-priority patent/GB9300816D0/en
Priority claimed from GB939319969A external-priority patent/GB9319969D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE199392T1 publication Critical patent/ATE199392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C12N2310/1241—Tetrahymena
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
AT94902030T 1992-12-04 1993-12-03 Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung ATE199392T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929225453A GB9225453D0 (en) 1992-12-04 1992-12-04 Binding proteins
GB939300816A GB9300816D0 (en) 1993-01-16 1993-01-16 Improvements in or relating to binding proteins
EP93303614 1993-05-10
GB939319969A GB9319969D0 (en) 1993-09-22 1993-09-22 Binding proteins iv
PCT/GB1993/002492 WO1994013804A1 (en) 1992-12-04 1993-12-03 Multivalent and multispecific binding proteins, their manufacture and use

Publications (1)

Publication Number Publication Date
ATE199392T1 true ATE199392T1 (de) 2001-03-15

Family

ID=27442661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902030T ATE199392T1 (de) 1992-12-04 1993-12-03 Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung

Country Status (10)

Country Link
US (2) US5837242A (de)
EP (1) EP0672142B1 (de)
JP (1) JP3720353B2 (de)
AT (1) ATE199392T1 (de)
AU (1) AU690528B2 (de)
CA (1) CA2150262C (de)
DE (1) DE69329974T2 (de)
DK (1) DK0672142T3 (de)
ES (1) ES2156149T3 (de)
WO (1) WO1994013804A1 (de)

Families Citing this family (1019)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
AU673335B2 (en) * 1991-08-05 1996-11-07 Igen, Inc. Prodrugs activated by targeted catalytic proteins
ATE463573T1 (de) * 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US20080152586A1 (en) * 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
JPH09503759A (ja) * 1993-09-22 1997-04-15 メディカル リサーチ カウンシル 抗体のリターゲッティング
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US20040018587A1 (en) * 1994-10-13 2004-01-29 Lee Makowski Nanostructures containing antibody assembly units
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
WO1996040724A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Recombinational cloning using engineered recombination sites
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU6873396A (en) * 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
DK0894135T3 (da) * 1996-04-04 2004-12-06 Unilever Nv Multivalent og multispecifikt antigenbindingsprotein
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US5977319A (en) * 1996-10-21 1999-11-02 Cambridge Antibody Technology Limited Specific binding members for estradiol; materials and methods
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
GB9710154D0 (en) * 1997-05-16 1997-07-09 Medical Res Council Detection of retroviruses
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US7011835B1 (en) 1997-07-10 2006-03-14 Research Development Foundation Targeted destruction of pests
DE69839492D1 (de) * 1997-09-11 2008-06-26 Chugai Pharmaceutical Co Ltd Monoklonale antikörper zur apoptosis-induzierung
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
DE69836092T2 (de) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
ATE461282T1 (de) * 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
EP1032660B1 (de) * 1997-11-17 2009-11-04 Micromet AG Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
WO1999025821A1 (en) 1997-11-18 1999-05-27 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
NZ504511A (en) * 1997-11-18 2002-12-20 Pioneer Hi Bred Int Recombinant proteins comprising fused first and second distinct site specific recombinase and use in methods for the integration of foreign DNA into eukaryotic genomes
US7102055B1 (en) 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
ATE454459T1 (de) 1997-11-18 2010-01-15 Pioneer Hi Bred Int Mobilisierung eines viralen genoms aus t-dna durch ortsspezifische rekombinationssysteme
DE69829995T2 (de) * 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002500879A (ja) * 1998-01-23 2002-01-15 イムクローン システムズ インコーポレーテッド 幹細胞の精製ポピュレーション
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
CA2329908A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California Targeted gene delivery to cells by filamentous bacteriophage
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EP1002861A1 (de) * 1998-10-26 2000-05-24 Unilever Plc Antigenbindungsproteine mit einer Kopplung, die die strukturelle Beweglichkeit einschränkt
US6610834B1 (en) * 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ATE519840T1 (de) 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2000039303A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Modified hiv env polypeptides
CA2358385C (en) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
DE60042969D1 (de) 1999-03-02 2009-10-29 Life Technologies Corp Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
CA2364997A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Encryption of traits using split gene sequences
WO2000053634A1 (fr) * 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2373815A1 (en) * 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
EP1194540A1 (de) * 1999-07-14 2002-04-10 Clontech Laboratories Inc. Rekombinase-basierende methoden zur herstellung von expressionsvektoren und zusammensetzungen für ihre verwendung
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
US7118745B1 (en) 1999-09-27 2006-10-10 The Regents Of The University Of California Engineering antibodies that bind irreversibly
EP1218413A4 (de) * 1999-09-27 2005-06-15 Univ California Antikörpermanipulation zur irreversiblen bindung
IL148936A0 (en) * 1999-10-20 2002-09-12 Genentech Inc Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
ATE391789T1 (de) 1999-12-10 2008-04-15 Invitrogen Corp Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
WO2001058955A1 (en) * 2000-02-10 2001-08-16 Research Development Foundation Targeted destruction of pests
EP1259548A1 (de) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK2199393T3 (da) * 2000-04-17 2012-11-26 Dyax Corp Hidtil ukendte fremgangsmåder til opbygning af biblioteker over genetiske pakker, der kollektivt viser medlemmerne af en forskelligartet familie af peptider, polypeptider eller proteiner
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7943129B2 (en) * 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
GB0022748D0 (en) 2000-09-15 2000-11-01 Allied Therapeutics Ltd Reducing the content of cells in a biological sample
US20030166160A1 (en) * 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
EP1324778A2 (de) * 2000-10-02 2003-07-09 Arizeke Pharmaceuticals, Inc. Zusammensetzungen und methoden zur transport von biologisch aktiven verbindungen über zelluläre barrieren
US7560622B2 (en) 2000-10-06 2009-07-14 Pioneer Hi-Bred International, Inc. Methods and compositions relating to the generation of partially transgenic organisms
US7393532B1 (en) 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
JP4261907B2 (ja) * 2000-10-20 2009-05-13 中外製薬株式会社 低分子化アゴニスト抗体
US8034903B2 (en) * 2000-10-20 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
PT2316940E (pt) 2000-12-18 2013-10-16 Dyax Corp Bibliotecas orientadas de pacotes genéticos
DE10063048A1 (de) * 2000-12-18 2002-07-11 Deutsches Krebsforsch Einzelketten-Antikörper mit verbesserter Stabilität
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002311756A1 (en) * 2001-01-18 2002-10-28 Clontech Laboratories, Inc. Sequence specific recombinase-based methods for producing intron containing vectors and compositions for use in practicing the same
CA2429397C (en) * 2001-01-26 2014-06-03 Commonwealth Scientific And Industrial Research Organisation Methods and means for producing efficient silencing construct using recombinational cloning
WO2002070678A2 (en) 2001-02-05 2002-09-12 Bayer Aktiengesellschaft Regulation of human serine/threonine protein kinase
CA2438515A1 (en) * 2001-02-15 2002-08-22 The Government Of The United States Of America Methods and compositions for inhibiting hiv-coreceptor interactions
WO2002072635A2 (en) * 2001-03-13 2002-09-19 University College London Specific binding members
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
JP2004531259A (ja) * 2001-04-19 2004-10-14 インヴィトロジェン コーポレーション 核酸分子の組換えクローニングのための組成物および方法
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
CA2448505A1 (en) * 2001-05-21 2002-11-28 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
AU2002316305A1 (en) * 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2452119C (en) * 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
EP1578917A4 (de) 2001-07-19 2008-01-23 Perlan Therapeutics Inc Multimere proteine und verfahren zu deren herstellung und verwendung
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1423012B1 (de) * 2001-08-10 2007-11-14 Imclone Systems, Inc. Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2005521380A (ja) * 2001-08-31 2005-07-21 カイロン コーポレイション 抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
EP1652920B1 (de) * 2001-10-01 2010-08-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
IL161417A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Affinity enhancement agents
PL374495A1 (en) * 2001-10-15 2005-10-31 Immunomedics, Inc. Direct targeting binding proteins
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
EP1314741B1 (de) * 2001-11-14 2007-03-07 Affimed Therapeutics AG Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
WO2003046560A2 (en) * 2001-11-30 2003-06-05 National Research Council Of Canada Self-assembly molecules
WO2003049684A2 (en) * 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
CA2478169C (en) * 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US20030186221A1 (en) * 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
CA2482173C (en) 2002-04-12 2012-10-23 Colorado School Of Mines Method for detecting low concentrations of a target bacterium that uses phages to infect target bacterial cells
EP1354600A1 (de) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antikörperkombination verwendbar für Tumortherapie
EP1534754A4 (de) * 2002-04-23 2005-12-21 Roger Williams Hospital Bispezifische antigenbindende zusammensetzungen und damit in zusammenhang stehende verfahren
EP1365034A3 (de) 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
AU2003239966B9 (en) * 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
NZ537579A (en) * 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
EP2301968A3 (de) 2002-06-14 2011-06-29 Immunomedics, Inc. Humanisierter monoklonaler Antikörper HPAM4
WO2004001065A2 (en) * 2002-06-24 2003-12-31 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
ATE541047T1 (de) 2002-08-01 2012-01-15 Univ California Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7897381B2 (en) * 2002-08-07 2011-03-01 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
ES2559763T3 (es) 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
JPWO2004033499A1 (ja) * 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7820787B2 (en) * 2003-01-23 2010-10-26 The Regents Of The University Of California Multi-functional antibodies
SK50642005A3 (sk) 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
WO2004069873A2 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
AU2004232928A1 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
EP2361928B1 (de) 2003-05-19 2017-04-26 Prothena Biosciences Limited Verkürzte Alpha-Synuklein-Fragmente in der Lewy-Körper-Krankheit
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AU2004250256B8 (en) * 2003-06-20 2010-04-08 Ambit Biosciences Corporation Assay and kits for detecting protein binding
US20050095615A1 (en) * 2003-06-26 2005-05-05 Welch Peter J. Methods and compositions for detecting promoter activity and expressing fusion proteins
DK1644493T3 (da) 2003-06-27 2010-09-13 Axikin Pharmaceuticals Inc Regulering af en kinase, 'reguleret i COPD kinase' (RC-kinase)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CA2533878A1 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2325339A3 (de) * 2003-09-09 2011-11-02 Integrigen, Inc. Verfahren und zusammensetzungen zur Erzeugung menschlicher keimlinien-Antikörpergene
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP1892306A3 (de) 2003-10-06 2008-06-11 Bayer HealthCare AG Verfahren und Kit zur Untersuchung von Krebs
US9382322B2 (en) 2003-10-17 2016-07-05 Rehab Al-Jamal Tissue repair by modulation of beta-1 integrin biological function
WO2005040386A2 (en) * 2003-10-23 2005-05-06 The Regents Of The University Of California A vector modification for versatile use of expressed products
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
ATE526037T1 (de) * 2003-12-04 2011-10-15 Vaccinex Inc Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
JP4898452B2 (ja) 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
US20070280951A1 (en) * 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
CA2553692C (en) * 2004-01-20 2014-10-07 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
MXPA06010715A (es) * 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7833731B2 (en) * 2004-03-31 2010-11-16 Canon Kabushiki Kaisha Gold-binding protein and use thereof
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005106035A2 (en) * 2004-04-09 2005-11-10 Cornell Research Foundation, Inc. Modular design and construction of nucleic acid molecules, aptamer-derived nucleic acid constructs, rna scaffolds, their expression, and methods of use
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005111081A2 (en) * 2004-05-10 2005-11-24 Egea Biosciences, Llc Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
RU2453558C2 (ru) 2004-09-03 2012-06-20 Дженентек, Инк. Гуманизированные антагонистические антитела против бета7 и их применение
ES2390676T3 (es) 2004-10-21 2012-11-15 Genentech, Inc. Método para el tratamiento de enfermedades neovasculares intraoculares
PL1817345T3 (pl) 2004-11-09 2009-10-30 Philogen Spa Przeciwciała przeciwko tenascynie-C
EP2325207B1 (de) 2004-11-12 2017-03-15 Xencor, Inc. Fc-varianten mit modifizierter bindung an fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
EP2377555A3 (de) * 2004-11-18 2011-11-23 Imclone LLC Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
MX2007007277A (es) * 2004-12-16 2008-01-28 Genentech Inc Metodos para tratar trastornos autoinmunes.
AU2005318183B2 (en) * 2004-12-22 2011-03-31 Merck Serono Sa Combination treatment for multiple sclerosis
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
EP1844144B1 (de) 2005-01-10 2010-04-14 MedImmune Limited Mutageneseverfahren
EP2153848A3 (de) 2005-01-27 2010-07-21 The Regents of the University of California Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
TW200722518A (en) * 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006105414A2 (en) 2005-03-31 2006-10-05 Colorado School Of Mines Apparatus and method for detecting microscopic organisms using microphage
CN103356707B (zh) 2005-03-31 2016-07-06 斯丹姆涅恩有限公司 制备用以治疗伤口或糖尿病性神经病引发的溃疡,或预防手术后疝形成的药物的方法
JP4838626B2 (ja) * 2005-04-28 2011-12-14 キヤノン株式会社 プラズモン共鳴を利用して標的物質を検出する装置に用いられる標的物質検出素子用基板、これを用いた検出素子及び検出装置
EP1927367A4 (de) * 2005-05-18 2009-08-12 Univ Tokushima Neues pharmazeutisches mittel mit anti-hla-antikörper
EP2949668B1 (de) 2005-05-18 2019-08-14 Ablynx N.V. Verbesserte nanokörper-tm gegen tumornekrosefaktor alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US9241994B2 (en) * 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
US7736897B2 (en) * 2005-07-18 2010-06-15 Pioneer Hi-Bred International, Inc. FRT recombination sites and methods of use
EP1749839A1 (de) 2005-07-22 2007-02-07 Novoplant GmbH Antigen-bindende Polypeptide gegen F4 (K88) fimbriae
SI2298815T1 (sl) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
WO2007024649A2 (en) * 2005-08-19 2007-03-01 X-Cell Medical Incorporated Methods of treating and preventing acute myocardial infarction
WO2007026972A2 (en) * 2005-09-01 2007-03-08 Canon Kabushiki Kaisha Binding protein molecule
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007062466A1 (en) * 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US20070143881A1 (en) * 2005-12-16 2007-06-21 Pioneer Hi-Bred International, Inc. Methods and Compositions for Improving the Efficiency of Site-Specific Polynucleotide Exchange
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
ES2363891T3 (es) 2006-03-20 2011-08-18 The Regents Of The University Of California Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
PL1999152T3 (pl) 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
EP4342995A2 (de) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
JP2007278748A (ja) * 2006-04-04 2007-10-25 Canon Inc 標的物質検出素子、検出材料、及び検出キット
AU2007249408A1 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CN101505793A (zh) * 2006-06-22 2009-08-12 瓦西尼斯公司 用于治疗癌症的抗c35抗体
EP2048230A4 (de) * 2006-07-13 2010-01-20 Chugai Pharmaceutical Co Ltd Zelltodinduzierer
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CN103524619B (zh) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
LT2511301T (lt) 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
JP5238710B2 (ja) 2006-10-19 2013-07-17 シーエスエル、リミテッド インターロイキン−１３レセプターアルファ１の高親和性抗体アンタゴニスト
CU23636A1 (es) 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP2102239B1 (de) * 2006-11-30 2012-04-25 Research Development Foundation Verbesserte immunglobulin-bibliotheken
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
JP5481199B2 (ja) * 2006-12-27 2014-04-23 ザ ジョンズ ホプキンス ユニバーシティー 炎症および自己免疫疾患を治療するための組成物および方法
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
ES2402171T3 (es) 2007-04-02 2013-04-29 Philogen S.P.A. El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales
WO2008143666A2 (en) 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
EP2641618A3 (de) 2007-07-16 2013-10-23 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
CN103212072B (zh) 2007-07-25 2015-07-22 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
WO2009026540A1 (en) 2007-08-22 2009-02-26 Colorado School Of Mines Lanthanide nanoparticle conjugates and uses thereof
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
BRPI0816785A2 (pt) * 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009039192A2 (en) 2007-09-17 2009-03-26 The Regents Of The University Of Californina Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
WO2009046388A1 (en) 2007-10-03 2009-04-09 United States Medical Research & Material Command Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
EP3783019A1 (de) 2007-10-30 2021-02-24 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
EP3192807A1 (de) 2007-11-27 2017-07-19 The University Of British Columbia 14-3-3-eta-antikörper und deren verwendung zur diagnose und behandlung von arthritis
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP3211010A1 (de) 2007-12-21 2017-08-30 Medimmune Limited Bindungselemente für interleukin-4-rezeptor-alpha (il-4r) - 173
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
US8697434B2 (en) 2008-01-11 2014-04-15 Colorado School Of Mines Detection of phage amplification by SERS nanoparticles
CA2713055C (en) 2008-01-25 2018-03-13 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
IL295449A (en) 2008-01-31 2022-10-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
EP2307563B1 (de) 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosa-gensignaturen
US9441204B2 (en) 2008-04-03 2016-09-13 Colorado School Of Mines Compositions and methods for detecting Yersinia pestis bacteria
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2722409C (en) 2008-04-24 2017-12-12 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
EP2279004B1 (de) * 2008-05-16 2015-01-14 F. Hoffmann-La Roche AG Verwendung von biomarkern zur beurteilung der behandlung von entzündlichen magen-darm-erkrankungen mit beta7-integrin-antagonisten
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
KR20110057244A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
EP2334705B1 (de) 2008-09-26 2016-12-14 UCB Biopharma SPRL Biologische produkte
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2376089B1 (de) 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
KR101093717B1 (ko) 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
US9527907B2 (en) 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US20120165340A1 (en) 2009-02-11 2012-06-28 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
CA2752510C (en) 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
AU2010215239A1 (en) 2009-02-23 2011-09-15 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
SG174353A1 (en) 2009-03-13 2011-11-28 Allergan Inc Immuno-based retargeted endopeptidase activity assays
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
GB0908425D0 (en) 2009-05-15 2009-06-24 Medical Res Council Medical use
CA2762837C (en) * 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2442827B1 (de) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsionsimpfstoffe
WO2011000543A1 (en) 2009-06-30 2011-01-06 Philochem Ag Murine antibody display library
EP2448599A1 (de) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokine in kombination mit anti-erbb-antikörpern für krebsbehandlung
EP2451479B1 (de) * 2009-07-06 2015-04-01 F.Hoffmann-La Roche Ag Bispezifische digoxigenin-bindungs-antikörper
ES2640981T3 (es) 2009-08-05 2017-11-07 Philogen S.P.A. Selección como diana de neovasculatura de médula ósea
WO2011019827A2 (en) 2009-08-11 2011-02-17 Academia Sinica Phage displaying system expressing single chain antibody
GB0914446D0 (en) 2009-08-18 2009-09-30 King S College London Bioconjugates and their uses in imaging
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
IN2012DN02753A (de) 2009-08-31 2015-09-18 Amplimmune Inc
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
NZ706187A (en) 2009-10-26 2016-09-30 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
EP3511023A1 (de) 2009-12-02 2019-07-17 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR20120105543A (ko) 2009-12-23 2012-09-25 4-안티바디 아게 인간 사이토메갈로바이러스에 대한 결합 멤버
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
LT2523688T (lt) 2010-01-15 2018-03-12 Kirin-Amgen, Inc. Antikūno kompozicija ir terapiniai režimai
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
US20110201076A1 (en) 2010-01-22 2011-08-18 Colorado School Of Mines Harvesting micro algae
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
PT2361936T (pt) 2010-02-25 2016-07-15 Affimed Gmbh Molécula que se liga a antigénio e utilizações desta
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SG184473A1 (en) * 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
NZ623714A (en) 2010-05-14 2015-10-30 Alltech Inc Yeast cell wall components and detection thereof
EP2808344A1 (de) 2010-06-01 2014-12-03 Monash University Auf die Rezeptor-Tyrosinkinase C-MET gerichtete Antikörper
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2011154705A1 (en) 2010-06-09 2011-12-15 Queen Mary & Westfield College Annexin 1 antibody
MX2013000083A (es) 2010-07-09 2013-02-26 Genentech Inc Anticuerpos de anti-neuropilina y metodos de uso.
WO2012007137A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
EP3741883B1 (de) 2010-07-16 2022-12-14 Adimab, LLC Antikörperbibliotheken
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
ES2678145T3 (es) 2010-08-24 2018-08-09 Abbott Laboratories Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
SG187953A1 (en) 2010-09-01 2013-03-28 Genzyme Corp Treatment of myocardial infarction using tgf - beta antagonists
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
EP2619319A2 (de) 2010-09-20 2013-07-31 Progenika Biopharma, S.A. Marker für gelenksdyspasie, osteoarthritis und sekundären erkrankungen
EP2621954A1 (de) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori-antikörper
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
KR101934247B1 (ko) 2010-10-18 2019-01-02 네스텍 소시에테아노님 항-약물 항체 동종형의 확인 방법
EP2629795B1 (de) 2010-10-19 2017-12-06 Mayo Foundation For Medical Education And Research Humane antikörper sowie diagnostische und therapeutische anwendungen davon zur behandlung neurologischer erkrankungen
EP2632492B1 (de) 2010-10-25 2017-10-04 Biogen MA Inc. Verfahren zur bestimmung von unterschieden in einer alpha-4-integrin-aktivität durch korrelation von unterschieden in svcam- und/oder smadcam-ebenen
GB201019118D0 (en) 2010-11-11 2010-12-29 King S College Conjugates and their uses in molecular imaging
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
CA2819038C (en) 2010-12-06 2023-10-17 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
JP2014508511A (ja) 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗ｉｌ−１８抗体およびそれらの使用
CU23895B1 (es) 2010-12-28 2013-05-31 Biorec Sa Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012107728A2 (en) 2011-02-09 2012-08-16 Cancer Research Technology Limited Frmd4a antagonists and their uses
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
EP2681243B1 (de) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6-rezeptor-antikörper und verfahren zu ihrer verwendung
US20140090094A1 (en) 2011-03-09 2014-03-27 Bayer Intellectual Property Gmbh Modulators of slc22a7
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
AP2013007046A0 (en) 2011-03-30 2013-08-31 Boehringer Ingelheim Int Anticoagulant antidotes
WO2012145630A2 (en) 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
EP2721070A1 (de) 2011-06-17 2014-04-23 Harris, Adrian, L. Verfahren zur verbesserung des ansprechverhaltens auf strahlung in der tumortherapie mit anti-dll4-antikörpern
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP2726101B1 (de) 2011-06-30 2018-08-08 Genzyme Corporation Inhibitoren der t-zellen-aktivierung
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
CA3158257A1 (en) 2011-07-11 2013-01-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
EP2548891A1 (de) 2011-07-18 2013-01-23 Universiteit Maastricht Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
RU2613368C2 (ru) 2011-07-22 2017-03-16 Аффимед Гмбх Поливалентная антиген-связывающая fv-молекула
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
GB201113482D0 (en) 2011-08-04 2011-09-21 Univ Liverpool Assay
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
DK2739649T3 (en) 2011-08-05 2018-01-08 Bioasis Technologies Inc P97 FRAGMENTS WITH TRANSFER ACTIVITY
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
AU2012296576B2 (en) 2011-08-15 2017-09-07 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
JP6251678B2 (ja) 2011-09-22 2017-12-20 アムジエン・インコーポレーテツド Ｃｄ２７ｌ抗原結合タンパク質
ES2826393T3 (es) 2011-10-05 2021-05-18 Univ Rockefeller Lisinas de bacteriófago diméricas
CN103906767A (zh) 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055985A1 (en) 2011-10-12 2013-04-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
CA2851284A1 (en) 2011-10-13 2013-04-18 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
JP6117225B2 (ja) 2011-11-02 2017-04-19 アペクシジェン， インコーポレイテッド 抗ｋｄｒ抗体およびその使用方法
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
EP2793944A4 (de) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobuline und varianten gegen pathogene mikroben
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
WO2013112676A1 (en) 2012-01-24 2013-08-01 THE UNITED STATES OF AMERECA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Schizophrenia-related isoform of knch2 and development of antipsycotic drugs
AU2013232114B2 (en) 2012-03-15 2018-10-18 Omeros Corporation Composition and method for diversification of target sequences
SI2833907T1 (en) 2012-04-06 2018-07-31 Omeros Corporation COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA
CN108285483B (zh) 2012-04-17 2022-04-26 梅奥医学教育和研究基金会 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
US9969813B2 (en) 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013183032A2 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
BR112014031522A2 (pt) 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014020293A1 (en) 2012-07-31 2014-02-06 Imperial Innovations Limited Assay
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
EP2692357A1 (de) 2012-08-03 2014-02-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Neuartige Anti-Plasmodium-Parasiten-Antikörper
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SG11201502404WA (en) 2012-10-03 2015-05-28 Philogen Spa Antigens associated with inflammatory bowel disease
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
EP2906597B1 (de) 2012-10-15 2020-04-08 Medimmune Limited Antikörper gegen amyloid beta
CN110066335B (zh) 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
SG11201502876RA (en) 2012-11-08 2015-06-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
US20140161790A1 (en) 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
SI2922872T1 (sl) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
EP2938728B1 (de) 2012-12-31 2020-12-09 Boehringer Ingelheim International GmbH Künstliche introne
WO2014102100A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within an immunoglobulin domain
MY173334A (en) 2013-01-02 2020-01-16 Ichnos Sciences SA Antibodies that bind to tl1a and their uses
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
ES2829499T3 (es) 2013-02-05 2021-06-01 Engmab Sarl Método para la selección de anticuerpos contra BCMA
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9902770B2 (en) 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3424952A1 (de) 2013-03-15 2019-01-09 Amgen, Inc Heterodimere bispezifische antikörper
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
NZ729747A (en) 2013-03-15 2020-03-27 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
GB201308259D0 (en) 2013-05-08 2013-06-12 Iles Raymond K Cancer diagnosis and monitoring
DE102013105144A1 (de) * 2013-05-17 2014-11-20 Arno Thaller Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
PT3004167T (pt) 2013-05-30 2018-11-13 Kiniksa Pharmaceuticals Ltd Proteínas de ligação ao antigénio do recetor da oncostatina m
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
GB201317207D0 (en) 2013-09-27 2013-11-13 Univ Glasgow Materials and methods for modulating disc1 turnover
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3055331B1 (de) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Konjugierte antikörper gegen ly75 zur behandlung von krebs
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
KR102331054B1 (ko) 2013-11-06 2021-11-24 얀센 바이오테크 인코포레이티드 항-ccl17 항체
WO2015082724A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3738981A1 (de) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Beta-klotho 2 bindende antikörper und verfahren zur verwendung davon
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
EP3102598A2 (de) 2014-02-04 2016-12-14 Contrafect Corporation Antikörper für passive influenzaimmunisierung, sowie zusammensetzungen, kombinationen und verfahren zur verwendung davon
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
EP3107935B1 (de) 2014-02-20 2020-06-24 Allergan, Inc. Antikörper der komplementkomponente c5
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
GB201403815D0 (en) 2014-03-04 2014-04-16 Mologic Ltd Assay
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
KR20160131073A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg4-5에 대해 특이적인 항-라미닌4 항체
EP3116906A1 (de) 2014-03-12 2017-01-18 Prothena Biosciences Limited Für lg1-3 spezifische anti-laminin4-antikörper
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
CR20160506A (es) 2014-03-28 2017-03-10 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP2930188A1 (de) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunktionelles Antigen-bindendes Molekül
GB201407132D0 (en) 2014-04-23 2014-06-04 Velgene Biotechnology Marker for neurodegenerative disorders
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
CA2955386A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3660042B1 (de) 2014-07-31 2023-01-11 Novartis AG T-zellen mit teilmengenoptimierten chimären antigenrezeptoren
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
CN112410363A (zh) 2014-08-19 2021-02-26 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
EP3191187B1 (de) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Kombinationstherapie mit anti-cd38-antikörpern
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US10040844B2 (en) 2014-10-22 2018-08-07 The Regents Of The University Of California Proteolytic release of cell surface antigens for phage biopanning
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
PE20171107A1 (es) 2014-11-07 2017-08-07 Eleven Biotherapeutics Inc Anticuerpos mejorados contra il-6
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
GB201420852D0 (en) 2014-11-24 2015-01-07 Genevillage Kft Method
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
DK3223845T3 (da) 2014-11-26 2021-08-16 Xencor Inc Heterodimere antistoffer, der binder cd3 og cd20
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
JP2018500553A (ja) 2014-12-05 2018-01-11 ネステク ソシエテ アノニム 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
WO2016092524A1 (en) 2014-12-11 2016-06-16 Inbiomotion S.L. Binding members for human c-maf
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
EP3237449A2 (de) 2014-12-22 2017-11-01 Xencor, Inc. Trispezifische antikörper
CN107427563B (zh) 2014-12-31 2021-03-02 财团法人生物技术开发中心 人源化α-烯醇酶特异性抗体及用于癌症治疗的方法
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
HUE049791T2 (hu) 2015-02-19 2020-10-28 Compugen Ltd PVRIG elleni antitestek és alkalmazási eljárások
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
GB201503967D0 (en) 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN115737104A (zh) 2015-03-31 2023-03-07 昂科赛克医疗公司 用于改进的基于组织感测的电穿孔的***和方法
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
EP3081575A1 (de) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium-parasiten-antikörper
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20160319009A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
PL3303394T3 (pl) 2015-05-29 2020-11-16 Agenus Inc. Przeciwciała anty-ctla-4 i sposoby ich zastosowania
EP3307772B1 (de) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
CR20170587A (es) 2015-06-22 2018-04-03 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
KR101750411B1 (ko) 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
AU2016291846B2 (en) 2015-07-13 2022-05-26 Compugen Ltd. HIDE1 Compositions and Methods
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
BR112018003186A2 (pt) 2015-09-01 2018-09-25 Agenus Inc. anticorpos anti-pd-1 e seus métodos de uso
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
CA2997963A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
US20190048089A1 (en) 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
EP3156417A1 (de) 2015-10-13 2017-04-19 Affimed GmbH Multivalente fv antikörper
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
KR20180093010A (ko) 2015-12-04 2018-08-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 새로운 암 치료용 항체
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
US20180355043A1 (en) 2015-12-17 2018-12-13 Janssen Biotech, Inc. Antibodies Specifically Binding HLA-DR and Their Uses
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3429620A1 (de) 2016-03-15 2019-01-23 AstraZeneca AB Kombination aus einem bac- inhibitor und einem antikörper- oder antigenbindenden fragment zur behandlung einer erkrankung im zusammenhang mit der akkumulation von amyloid beta
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
WO2017181119A2 (en) 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective protein expression
WO2017189751A1 (en) 2016-04-26 2017-11-02 The University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
PL3458478T3 (pl) 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
EP3464354B1 (de) 2016-06-02 2021-07-28 Bloom Diagnostics AG Antikörper zur bindung an humane anti-müller-hormone (amh) und deren verwendungen
WO2017208018A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478716A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
US20190227082A1 (en) 2016-07-06 2019-07-25 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
CN117330747A (zh) 2016-07-15 2024-01-02 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US10478497B2 (en) 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
SG11201900677SA (en) 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US20190352426A1 (en) 2016-08-03 2019-11-21 Achaogen, Inc. Plazomicin antibodies and methods of use
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MA46200A (fr) 2016-09-06 2019-07-17 Chugai Pharmaceutical Co Ltd Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
CA3036835A1 (en) * 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
EP3523331A1 (de) 2016-10-07 2019-08-14 Novartis AG Chimäre antigenrezeptoren zur behandlung von krebs
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3526241A1 (de) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r-heterodimere fc-fusionsproteine
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
GB201617723D0 (en) 2016-10-19 2016-11-30 Univ London Queen Mary Method for predicting prostate cancer metastasis
GB201617722D0 (en) 2016-10-19 2016-11-30 Univ London Queen Mary Method for determining prognosis of cancer
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CA3042989A1 (en) 2016-11-07 2018-05-11 Junho Chung Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3535288A1 (de) 2016-11-07 2019-09-11 Immunocore Limited Peptide
JP6925431B2 (ja) 2016-11-09 2021-08-25 フィロジェン エッセ．ピー．アー． Ｉｌ２及びｔｎｆ突然変異体のイムノコンジュゲート
US11448648B2 (en) 2016-11-11 2022-09-20 Ascendant Diagnostics, LLC Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and Kawasaki disease
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
BR112019014986A8 (pt) 2017-01-23 2022-10-18 Carsgen Therapeutics Co Ltd Anticorpo que alveja bcma e uso do mesmo
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3589647A1 (de) 2017-02-28 2020-01-08 Novartis AG Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
EP3610010A4 (de) 2017-04-14 2021-02-24 Kodiak Sciences Inc. Komplementfaktor-d-antagonisten-antikörper und konjugate davon
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
PL3618863T3 (pl) 2017-05-01 2023-11-06 Agenus Inc. Przeciwciała anty- tigit i sposoby ich zastosowania
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
US11149094B2 (en) 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
PE20200294A1 (es) 2017-06-05 2020-02-05 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y metodos de uso
US11390666B2 (en) 2017-06-07 2022-07-19 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
EP3652209A2 (de) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
CA3074317A1 (en) 2017-08-25 2019-02-28 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
KR20200074127A (ko) 2017-11-02 2020-06-24 옥스포드 바이오테라퓨틱스 리미티드 항체 및 사용 방법
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
CN109796532A (zh) 2017-11-17 2019-05-24 科济生物医药（上海）有限公司 靶向成纤维激活蛋白α的结合单元及其应用
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
AU2019211121A1 (en) 2018-01-26 2020-08-27 Cambridge Enterprise Limited Peptide exchange protein
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
CN112154156A (zh) 2018-03-28 2020-12-29 武田药品工业株式会社 抗cd38抗体的皮下给药
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
SG11202010064QA (en) 2018-04-13 2020-11-27 Affimed Gmbh Nk cell engaging antibody fusion constructs
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR102097994B1 (ko) 2018-04-25 2020-04-07 아이디바이오 주식회사 신규한 중증열성혈소판감소증후군 바이러스
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
MX2020011468A (es) 2018-04-30 2021-02-09 Medimmune Ltd Conjugados para detectar selectivamente y eliminar agregados.
TW201946652A (zh) 2018-05-09 2019-12-16 瑞士商諾華公司 康納單抗(canakinumab)之用途
CN112368019A (zh) 2018-05-16 2021-02-12 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
EP3569618A1 (de) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisierender cd73-antikörper
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3802609A2 (de) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma-bindende stoffe und verwendungen davon
EA202092847A1 (ru) 2018-05-24 2021-04-20 Янссен Байотек, Инк. Антитела к cd3 и их применение
JP2021524255A (ja) 2018-05-24 2021-09-13 ヤンセン バイオテツク，インコーポレーテツド 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
WO2020011759A1 (en) 2018-07-09 2020-01-16 Ichnos Sciences S.A. Methods to determine the monoclonality of a cell population
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019312576A1 (en) 2018-08-01 2021-02-25 Cephalon, LLC Anti-CXCR2 antibodies and uses thereof
EP3849513A1 (de) 2018-09-11 2021-07-21 Ichnos Sciences SA Zusammensetzungen mit einem bispezifischen antikörper, pufffer und einem oder mehreren stabilisierenden mitteln
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
EP3660039A1 (de) 2018-11-30 2020-06-03 Philogen S.p.A. Il2-immunkonjugate
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
US11929171B2 (en) 2018-10-18 2024-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof
EP3867273A1 (de) 2018-10-19 2021-08-25 Ichnos Sciences SA T-zell-umleitender bispezifischer antikörper zur behandlung von plattenepithelkarzinomen
WO2020095104A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
CN113166269A (zh) 2018-11-13 2021-07-23 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
MA54248A (fr) 2018-11-13 2021-09-22 Janssen Biotech Inc Régulation de métaux traces pendant la production d'anticorps anti-cd38
EP3886869A4 (de) 2018-11-28 2022-07-06 Forty Seven, Inc. Genetisch modifizierte ablationsresistente hspcs
EP3898686A1 (de) 2018-12-20 2021-10-27 Novartis AG Pharmazeutische kombinationen
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
TW202031684A (zh) 2018-12-20 2020-09-01 日商協和麒麟股份有限公司 Fn14抗體及其用途
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
BR112021011351A2 (pt) 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US11071860B2 (en) 2019-02-06 2021-07-27 Oncosec Medical Incorporated Systems and methods for detecting fault conditions in electroporation therapy
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
JP2022521428A (ja) 2019-02-25 2022-04-07 ザ・ユニバーシティ・オブ・シカゴ 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
US11242407B2 (en) 2019-02-26 2022-02-08 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EP3930850A1 (de) 2019-03-01 2022-01-05 Xencor, Inc. Enpp3 und cd3 bindende heterodimere antikörper
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
AU2020235455A1 (en) 2019-03-08 2021-10-28 Oxford Genetics Limited Method of selecting for antibodies
MX2021011830A (es) 2019-03-29 2022-01-24 Atarga Llc Anticuerpo anti fgf23.
GB201904717D0 (en) 2019-04-03 2019-05-15 Univ London Queen Mary Treatment and diagnosis of mental disorders
CA3136892A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
BR112021024402A2 (pt) 2019-06-03 2022-02-15 Univ Chicago Métodos e composições para tratamento de câncer com adjuvantes direcionados ao câncer
AR120054A1 (es) 2019-06-10 2022-02-02 Takeda Pharmaceuticals Co Politerapias con anticuerpos de cd-38
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CA3143680A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
EP3990919B1 (de) 2019-06-25 2023-09-13 Actome GmbH Verfahren und kit zur messung von analyten in zweikomponentensystemen und deren verwendung
US20220372137A1 (en) 2019-07-03 2022-11-24 Oxford Biotherapeutics Ltd Antibodies and methods of use
GB201910138D0 (en) 2019-07-15 2019-08-28 Capella Bioscience Ltd Anti-pd-l1 antibodies
US20220273796A1 (en) 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
EP3766481A1 (de) 2019-07-19 2021-01-20 Ichnos Sciences SA Flüssige antikörperformulierung
KR20220041881A (ko) 2019-07-29 2022-04-01 컴퓨젠 엘티디. 항-pvrig 항체 제제 및 이의 용도
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP3786174A1 (de) 2019-08-27 2021-03-03 Ichnos Sciences SA Verfahren zur antikörperaufreinigung
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
JP2022550067A (ja) 2019-09-27 2022-11-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｅａｃａｍ抗体及びその使用
JP2022550121A (ja) 2019-09-29 2022-11-30 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｌｉｆに特異的な結合分子及びその使用
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP4041312A4 (de) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Verfahren zur behandlung einer augenstörung
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
WO2021076930A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4048285A1 (de) 2019-10-21 2022-08-31 Novartis AG Tim-3-inhibitoren und verwendungen davon
EP4054632A1 (de) 2019-11-04 2022-09-14 Compugen Ltd. Kombinationstherapie mit anti-pvrig-antikörperformulierungen und anti-pd-1-antikörpern
EP3822366A1 (de) 2019-11-13 2021-05-19 Ichnos Sciences SA Verfahren zur bestimmung der monoklonalität einer zellpopulation
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
AU2020393912A1 (en) 2019-11-26 2022-06-09 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022013589A2 (pt) 2020-01-08 2022-09-13 Regeneron Pharma Tratamento da fibrodisplasia ossificante progressiva
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
US20210222244A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
CN115087668A (zh) 2020-01-31 2022-09-20 奥斯瓦道·克鲁兹基金会 抗体、其用途、药物组合物，包括真菌感染诊断方法、真菌感染诊断试剂盒和真菌感染治疗方法
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
JP2023515211A (ja) 2020-02-27 2023-04-12 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
KR20220154140A (ko) 2020-03-13 2022-11-21 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pvrig 결합 단백질 및 이의 의학적 용도
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
WO2021211753A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
BR112022023392A2 (pt) 2020-05-19 2022-12-20 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit
KR20230024972A (ko) 2020-06-12 2023-02-21 아이크노스 사이언스 에스. 아. 항체 제형 희석제
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
EP4169949A1 (de) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38-antikörper und verwendung davon
EP3933035A1 (de) 2020-07-03 2022-01-05 Aarhus Universitet Zusammensetzungen mit extrazellulären vesikeln und sting-stimulatorischen mitteln
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
GB202012512D0 (en) 2020-08-11 2020-09-23 Univ College Dublin Nat Univ Ireland Dublin B-1,4 Galactosylation of proteins
MX2023002001A (es) 2020-08-18 2023-03-21 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos.
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022053697A1 (en) 2020-09-14 2022-03-17 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
BR112023004830A2 (pt) 2020-09-16 2023-04-18 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
CN116648463A (zh) 2020-09-18 2023-08-25 伊克诺斯科学公司 Cd47-cd38双特异性抗体
US20230365680A1 (en) 2020-09-30 2023-11-16 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20220119535A1 (en) 2020-10-21 2022-04-21 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
WO2022090801A2 (en) 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
EP4242233A1 (de) 2020-11-06 2023-09-13 Korea University Research and Business Foundation Fc-alpha-rezeptorbindender antikörper
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
US20240053250A1 (en) 2020-12-16 2024-02-15 Juno Therapeutics, Inc. Threshold gating for flow cytometry methods
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
EP4284516A1 (de) 2021-01-28 2023-12-06 Compugen Ltd. Anti-pvrig-antikörperformulierungen und verwendungen davon
US20240076373A1 (en) 2021-01-28 2024-03-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
EP4304644A1 (de) 2021-03-09 2024-01-17 Janssen Biotech, Inc. Behandlung von krebserkrankungen ohne egfr-aktivierende mutationen
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4314016A1 (de) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Zyklische zellen penetrierende peptide
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022214089A1 (zh) 2021-04-08 2022-10-13 克莱格医学有限公司 细胞免疫治疗的应用
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2022220603A1 (ko) 2021-04-16 2022-10-20 고려대학교 산학협력단 코로나-19 바이러스 표적 인간 항체
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2022223824A1 (en) 2021-04-23 2022-10-27 Philogen S.P.A Anti-fibroblast activation protein antibodies
KR20240012425A (ko) 2021-05-10 2024-01-29 엔트라다 테라퓨틱스, 인크. 세포내 치료제를 위한 조성물 및 방법
EP4337676A1 (de) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigenbindende und antigenabbauende konstrukte
EP4337263A1 (de) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
WO2022245859A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
CN117412767A (zh) 2021-05-25 2024-01-16 雪绒花免疫公司 C-x-c基序趋化因子受体6（cxcr6）结合分子及其使用方法
WO2022248835A1 (en) 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
AU2022293999A1 (en) 2021-06-14 2023-11-30 argenx BV Anti-il-9 antibodies and methods of use thereof
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
WO2023275621A1 (en) 2021-07-01 2023-01-05 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
IL310024A (en) 2021-08-02 2024-03-01 Hangzhou Unogen Biotech Ltd Anti-CD38 antibodies, anti-CD3 antibodies, bispecific antibodies and their uses
WO2023015169A1 (en) 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
AU2022334794A1 (en) 2021-08-25 2024-03-28 Iontas Limited Preparation of libraries of protein variants expressed in eukaryotic cells
KR20230031015A (ko) 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
WO2023043123A1 (ko) 2021-09-17 2023-03-23 고려대학교 산학협력단 Fcγrⅲa 선택적 결합력 향상 당화 fc 변이체들
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CA3232216A1 (en) 2021-10-18 2023-04-27 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
US20230183360A1 (en) 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023213998A1 (en) 2022-05-06 2023-11-09 Ichnos Sciences SA Cd3/bcma/cd38 trispecific antibodies
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023230532A1 (en) 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation
WO2023232857A1 (en) 2022-06-03 2023-12-07 Ichnos Sciences SA Common light chain antibody libraries
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US20240076343A1 (en) 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024003114A1 (en) 2022-06-29 2024-01-04 Actome Gmbh Detection of biomolecules in single cells
WO2024003837A1 (en) 2022-06-30 2024-01-04 Janssen Biotech, Inc. Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
GB202209867D0 (en) 2022-07-05 2022-08-17 Univ Nottingham Disruption of epithelial barriers for molecular delivery enhancement or extraction of extracellular fluids
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024018069A1 (en) 2022-07-22 2024-01-25 Philogen S.P.A Anti-cd28 antibodies
EP4311557A1 (de) 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Auf fap abzielende antikörper-arzneimittelkonjugate
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024079711A1 (en) 2022-10-14 2024-04-18 Janssen Research & Development, Llc Method for detection of antibody-dependent cellular phagocytosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB2197065A (en) * 1986-11-03 1988-05-11 Stc Plc Optical sensor device
ATE114723T1 (de) * 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
EP0623679B1 (de) * 1987-05-21 2003-06-25 Micromet AG Multifunktionelle Proteine mit vorbestimmter Zielsetzung
AU652539B2 (en) * 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
AU7766391A (en) * 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
NZ314630A (en) * 1991-01-17 2000-11-24 Harvard College Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell
EP0617706B1 (de) * 1991-11-25 2001-10-17 Enzon, Inc. Multivalente antigen-bindende proteine
ATE463573T1 (de) * 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0626999A4 (en) * 1992-01-24 1997-04-09 Life Technologies Inc Modulation of enzyme activities in the -i(in vivo) cloning of dna.
ATE295420T1 (de) * 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
EP0628082B1 (de) * 1992-02-26 2001-05-16 Zeneca Mogen B.V. Zur ortsspezifischen rekomination fähige agrobakterium stämme
CA2131151A1 (en) * 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
EP1550729B1 (de) * 1992-09-25 2009-05-27 Avipep Pty Limited Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist

Also Published As

Publication number Publication date
CA2150262A1 (en) 1994-06-23
US6010884A (en) 2000-01-04
JP3720353B2 (ja) 2005-11-24
CA2150262C (en) 2008-07-08
WO1994013804A1 (en) 1994-06-23
US5837242A (en) 1998-11-17
DE69329974D1 (de) 2001-04-05
JPH08504100A (ja) 1996-05-07
DE69329974T2 (de) 2001-07-19
AU5654894A (en) 1994-07-04
EP0672142B1 (de) 2001-02-28
EP0672142A1 (de) 1995-09-20
ES2156149T3 (es) 2001-06-16
DK0672142T3 (da) 2001-06-18
AU690528B2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ATE199392T1 (de) Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
ATE377027T1 (de) Tetravalente antikörperkonstrukte
Mertens Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals
NZ612796A (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
DE69327229D1 (de) Multivalente einkettige Antikörper
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
DK2036926T3 (da) Enkeltkædet molekyle, der kan binde til flere antigener, dettes fremstilling og anvendelse
WO2004065416A3 (en) Synthetic antibody phage libraries
DE58909458D1 (de) Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung.
ATE213837T1 (de) Polypeptid-dendrimer komplexe
AR077088A1 (es) Proteinas biespecificas de union a antigeno
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
NO961151D0 (no) Antistoffer mot CD40
SI2573121T1 (en) IL-4 and / or IL-13 binding antibodies and their uses
RS52484B (en) CD40 ANTIBODIES
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
ATE166883T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
DE69534941D1 (de) Herstellung einer multikombinatorischen bank von antikörpergene-exprimierende vektoren
ATE300617T1 (de) Fibronektinbindungsprotein, monoklonaler antikoerper und ihre verwendung zur verhuetung der adhäsion von bakterien
DK0501215T3 (da) Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification